Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan and Chemotherapy in Chinese R/R AML
NCT04839341Phase 1Completed
- Sponsor
- Apollomics, Inc.
- Start
- Feb 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of uproleselan in acute myeloid leukemia (AML), sponsored by Apollomics, Inc. Primary endpoints: Peak plasma concentration (Tmax) at 14 days, Peak plasma concentration (Cmax) at 14 days and 4 more. Started Feb 2021; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04839341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839341.